| Literature DB >> 34072634 |
Chien-Ning Hsu1,2, You-Lin Tain3,4.
Abstract
Increasing evidence suggests that fetal programming through environmental exposure during a critical window of early life leads to long-term detrimental outcomes, by so-called developmental origins of health and disease (DOHaD). Hypertension can originate in early life. Animal models are essential for providing convincing evidence of a causal relationship between diverse early-life insults and the developmental programming of hypertension in later life. These insults include nutritional imbalances, maternal illnesses, exposure to environmental chemicals, and medication use. In addition to reviewing the various insults that contribute to hypertension of developmental origins, this review focuses on the benefits of animal models in addressing the underlying mechanisms by which early-life interventions can reprogram disease processes and prevent the development of hypertension. Our understanding of hypertension of developmental origins has been enhanced by each of these animal models, narrowing the knowledge gap between animal models and future clinical translation.Entities:
Keywords: animal model; developmental origins of health and disease (DOHaD); gut microbiota; hypertension; oxidative stress; pregnancy; renin-angiotensin system; reprogramming
Year: 2021 PMID: 34072634 PMCID: PMC8227380 DOI: 10.3390/biomedicines9060623
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Schematic illustration of the selection of animal models for studying hypertension of developmental origins in adulthood according to early-life environmental insults, animal species, and common mechanisms. Lines with arrows (top section) indicate types of early-life insults produced in particular species of animals to induce hypertension in adult offspring. The study of other animals in DOHaD research (non-human primates, rabbits, pigs, etc.) is limited.
Figure 2Overview of nutritional interventions used to modulate nutritional status during pregnancy and/or lactation to study hypertension of developmental origins in animal models. Fe = iron; Zn = zinc; Vit D = vitamin D; Na = sodium; Ca = calcium.
Summary of animal models of the developmental programming of hypertension, categorized according to maternal illness and pregnancy complications.
| Maternal Illnesses and Conditions | Animal Models | Species/Gender | Age at Hypertension Development | Ref. |
|---|---|---|---|---|
| Hypertensive disorders of pregnancy | Genetic hypertension model | SHR/M | 12 weeks | [ |
| 2-kidney, 1-clip renovascular hypertension model | SD rat/M,F | 16 weeks | [ | |
| Preeclampsia | Intraperitoneal administration of 60 mg/kg suramin on gestational days 10 and 11 | SD rat/M | 12 weeks | [ |
| Subcutaneous administration of 60 mg/kg L-NAME during pregnancy | SD rat/M | 12 weeks | [ | |
| Reduced uterine perfusion | SD rat/M | 16 weeks | [ | |
| Chronic kidney disease | 0.5% adenine supplementation from 3 weeks before pregnancy until 3 weeks after delivery | SD rat/M | 12 weeks | [ |
| Type 1 diabetes | Single intraperitoneal injection of 45 mg/kg STZ on gestational day 0 | SD rat/M | 12 weeks | [ |
| Single intraperitoneal injection of 35 mg/kg STZ on gestational day 0 | SD rat/M | 6 months | [ | |
| Type 2 diabetes | Mother rat received single intraperitoneal injection of 50 mg/kg STZ at newborn stage | SD rat/M | 12 weeks | [ |
| Anemia | Iron-deficiency diet from 4 weeks before pregnancy until delivery | Rowett hooded Lister rat/M & F | 16 weeks | [ |
| Polycystic ovary syndrome | Subcutaneous injection of 5 mg/kg testosterone cypionate on gestational day 20 | Wistar rat/F | 120 days | [ |
| Maternal inflammation | Intraperitoneal administration of 0.79 mg/kg LPS on gestational days 8, 10, and 12 | SD rat/M & F | 12 weeks | [ |
| Intraperitoneal injection of 2.37 mg/kg zymosan on gestation days 8, 10, and 12 | SD rat/M | 66 weeks | [ | |
| Maternal hypoxia | Hypoxia maintained at constant inspired fraction of oxygen of 13% from gestational day 6 to 20 | Wistar rat/M | 4 months | [ |
| Hypoxia maintained at 10% oxygen from gestational day 105 to 145 | Sheep/F | 9 months | [ | |
| Sleep disorder | Sleep restriction | Wistar rat/M | 3 months | [ |
| 24 h constant light exposure during pregnancy | SD rat/M | 12 weeks | [ |
Studies tabulated according to types of maternal illnesses and conditions, animal model, and age at evaluation. L−NAME = NG-nitro-L-arginine-methyl ester; STZ = streptozotocin; LPS = lipopolysaccharide; SHR = spontaneously hypertensive rat; SD = Sprague-Dawley.
Summary of animal models of the developmental programming of hypertension, categorized according to chemical and medication exposure.
| Chemical or Medication | Animal Models | Species/Gender | Age at Hypertension Development | Ref. |
|---|---|---|---|---|
| TCDD | Oral administration of 200 ng/kg TCDD on gestational days 14 and 21 and postnatal days 7 and 14 | SD rat/M | 12 weeks | [ |
| Oral administration of 200 ng/kg TCDD on gestational days 14 and 21 and postnatal days 7 and 14 | SD rat/M | 16 weeks | [ | |
| Bisphenol A | Oral administration of 50 μg/kg/day bisphenol A during pregnancy and lactation | SD rat/M | 16 weeks | [ |
| Nicotine | Nicotine administration via osmotic mini-pump at 4 μg/kg/min from gestational day 4 to postnatal day 10 | SD rat/M | 8 months | [ |
| Alcohol | Ethanol 1 g/kg by oral gavage on gestational days 13.5 and 14.5 | SD rat/M,F | 6 months | [ |
| Caffeine | Subcutaneous injection of 20 mg/kg caffeine daily during pregnancy | C57BL/6 mouse/M | 3 months | [ |
| Cyclosporine | Cyclosporine 3.3 mg/kg from gestational day 10 to postnatal day 7 | SD rat/M | 11 weeks | [ |
| Gentamicin | Subcutaneous injection of 110 mg/kg gentamicin from gestational day 10 to 15 or 15 to 20 | SD rat/F | 1 year | [ |
| Minocycline | Minocycline 50 mg/kg via oral gavage during pregnancy and lactation | SD rat/M | 12 weeks | [ |
| Tenofovir | Tenofovir 100 mg/kg diet from 1 week before mating and during pregnancy | Wistar rat/M | 6 months | [ |
| Glucocorticoid | Intraperitoneal injection of 0.2 mg/kg dexamethasone on gestational days 15 and 16 | SD rat/M | 12 weeks | [ |
| Intraperitoneal injection of 0.1 mg/kg dexamethasone from gestational day 16 to 22 | SD rat/M | 12 weeks | [ | |
| Intraperitoneal injection of 0.5 mg/kg dexamethasone on postnatal day 1, 0.3 mg/kg on day 2, and 0.1 mg/kg on day 3. | SD rat/M | 12 weeks | [ | |
| Intramuscular injection of 0.17 mg/kg betamethasone on gestational days 80 and 81 | Sheep/M,F | 18 months | [ | |
| Intravenous treatment with 0.48 mg/h dexamethasone for 48 h on gestational day 27 | Sheep/M,F | 16 months | [ |
Studies tabulated according to type of chemical or medication, animal model, and age at evaluation. TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin; SD = Sprague-Dawley.